Byoung Chul Cho

2 months ago | brnw.ch | Byoung Chul Cho |Byoung Chul |Juan Li

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Jan 8, 2025 | oncodaily.com | Byoung Chul Cho

Rami Manochakian shared a post on X:“Hot off the press. Just published in the Journal of Clinical Oncology. Results of TROPION/Lung05 Phase 2 trial of Datopotamab Deruxtecan in:Advanced Non–Small Cell Lung Cancer with Actionable Genomic Alterations with progression after Targeted Therapy and Chemotherapy.

Jan 6, 2025 | lifestyle-medicine.mednet.co.il | Byoung Chul Cho |Byoung Chul |Jacob Sands

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Jan 6, 2025 | brnw.ch | Byoung Chul Cho |Byoung Chul |Jacob Sands

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Dec 6, 2024 | oncodaily.com | Byoung Chul Cho

Durvalumab (brand name Imfinzi) is a monoclonal antibody developed by Medimmune, a part of AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody designed to block the interaction between programmed cell death ligand 1 (PD-L1) and PD-1 (CD279) receptors on T-cells. By inhibiting this interaction, durvalumab helps to activate the immune system to target and destroy cancer cells.